A Phase I Study of GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Participants With Selected Relapsed/Refractory GPNMB-Expressing Solid Tumours

Study Summary

Only enrolling in Canada. The purpose of this study is to identify the highest dose of GCAR1, a chimeric antigen receptor (CAR-T) cell therapy, that can be tolerated without causing very severe side effects, and to see what effects GCAR1 has on selected cancers

Interventions

Study Locations

Facility	City	State	Country
Arthur J.E. Child Comprehensive Cancer Centre	Calgary	Alberta	Canada
Ottawa Hospital Research Institute	Ottawa	Ontario	Canada
University Health Network Princess Margaret Hospital	Toronto	Ontario	Canada

Official Trial Information

View on ClinicalTrials.gov